Key Takeaways:
- The new test helps de-risk cell and gene therapy programs by providing early data on viral vector design and manufacturability, potentially preventing costly late-stage failures.
- With turnaround times of three to five weeks, the service is intended to accelerate candidate selection and feasibility assessments, addressing a key bottleneck in the development timeline.
- The offering aims to strengthen the data package for Chemistry, Manufacturing, and Controls (CMC), a critical component for regulatory approval in advanced therapies.
As the cell and gene therapy (CGT) sector expands, biopharmaceutical companies face significant pressure to accelerate development timelines while mitigating the high financial risks associated with late-stage manufacturing failures. Early decisions regarding vector design and scalability can have profound impacts on the viability of a therapeutic program, particularly when preparing for the stringent requirements of Chemistry, Manufacturing, and Controls (CMC) submissions to regulatory bodies.
Addressing this industry challenge, contract development and manufacturing organization ProBio Inc. has launched a Viral Vector Packaging Test. The service is designed to provide developers with essential data at a critical inflection point, moving from discovery to process development.
The test supports multiple viral vector modalities, including lentiviral vectors (LVV) used for CAR T applications and adeno-associated viruses (AAV) common in gene therapy. According to the company, the service uses its platform processes to enable a comparative evaluation of packaging strategies with turnaround times as short as three to five weeks. This rapid feedback loop is intended to inform candidate selection, assess feasibility, and generate samples for early pharmacology studies.
Making informed choices early in the development cycle is crucial for long-term success and regulatory compliance. "Early development choices have lasting impact on the success of cell and gene therapy programs," said Huiyi Zhu, Global Line Manager for Viral Vector at ProBio Inc. "This new packaging test reflects our commitment to providing biopharma innovators with practical data, technical confidence, and a clear path forward, using the same systems they can later take into CMC and clinical development."
The launch follows the 2025 opening of ProBio's viral vector facility in Hopewell, New Jersey, and represents a continued investment in the advanced therapies manufacturing space. By providing robust manufacturability data upfront, such services aim to streamline the complex path from the lab to clinical trials and eventual commercialization.
